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Duchennemuscular dystrophy (DMD) is a progressive, fatal, X-linked
monogenicmuscle disorder caused bymutations in theDMD gene. In
order to test treatments for DMD, a range of natural and engineered
animal models have been developed, including mice, rats, dogs and
pigs. Sui and colleagues have nowadded a dystrophic rabbit model to
this range using CRISPR/Cas9 to disrupt exon 51 of DMD. Rabbits
have the advantage of being easier to breed and less costly than dog
or pig models, but having clear clinical signs, in contrast to many
mouse models. There appears to be an effect of body size in models
of DMD, as the severity of the clinical signs increases with increasing
body size across species. All DMD models have advantages and
disadvantages, and it is crucial that investigators understand the
limitations of each model when testing novel therapies for DMD in
pre-clinical studies.
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Duchenne muscular dystrophy (DMD) is a progressive, fatal,
X-linked monogenic muscle disorder that results in progressive
muscle wasting and fibro-fatty replacement of muscle. It affects
between 1 in 3500 to 1 in 5000 live male births. The disorder is
caused by mutations in DMD, a 2.3 Mb gene encoding the
427 kD protein called dystrophin that sits just below the muscle
cell membrane (sarcolemma). In DMD, most of the mutations
lead to the loss of the open reading frame and thus a failure to
produce a stable protein. DMD also encodes a variety of smaller
isoforms that play important roles in other tissues, including the
central nervous system. The full-length dystrophin is believed to
have both a structural and signalling role in striated muscle. In the
absence of dystrophin, the muscle is prone to damage when
contracting, possibly exacerbated by the absence of activity-
induced hyperaemia, owing to the mislocalisation of neuronal
nitric oxide synthase. The inflammation associated with muscle
damage leads to progressive fibrosis, loss of muscle fibres
and replacement with fat. DMD is often not diagnosed until
4-5 years of age, although neonatal screening programs can
detect massively increased creatine kinase levels leaking from
damaged muscles, which is subsequently confirmed by
molecular analysis of the DMD gene. Prior to diagnosis,
affected boys most commonly present with a delay in the major
motor milestones and might never run. The weakness of muscles
starts proximally, especially in the lower limbs and this leads to
the classic Gower’s manoeuvre, in which affected boys use their
arms to straighten their legs and back when rising from the floor.
Untreated patients lose independent ambulation by 13 years of age
and many do so much earlier. The heart is also affected, and
cardiomyopathy is a problem for all DMD patients. Current medical
management includes the use of intermittent or daily steroids,
medication to counter the cardiomyopathy, assisted ventilation
(especially at night) and spinal surgery, if necessary, to maintain
ventilation volume. Corticosteroids slow the rate of disease
progression but have significant side effects. Under optimal
medical management, patients have an improved quality of life and
increased longevity. Currently, patients survive into their late 20s or
early 30s on average, but a number of patients survive for more than
40 years. In all cases, patients become progressively weaker and
increasingly dependent on their carers.
A number of different approaches are being taken for the
development of targeted therapies for DMD, with the aim of
preventing disease progression or reversing some of the disease-
associated pathology. Although compounds can be screened in cell
and tissue cultures, the use of animal models is key to understanding
the potential efficacy of different DMD therapies. A wide range of
mammalianmodels have been discovered or generated for DMD. The
best known is the dystrophic mdx mouse, which has a premature stop
mutation in exon 23 of the murine Dmd gene and consequently fails
to produce dystrophin (Sicinski et al., 1989). The mdx mouse has
been the most widely used model of DMD, with more than 2800
papers published using this mouse. Although the mdx mouse is a
good biochemical model of DMD and shows elements of the early
stages of the disease, the mice have only a slightly shortened life span
and show no obvious clinical signs of muscular dystrophy.
The original mdx has been backcrossed onto a variety of genetic
backgrounds that appear very similar to the original mdx mouse.
A backcross onto the DBA/2J appears to worsen the phenotype of
the dystrophic mouse, such as lower hind limb muscle weight, fewer
myofibres, increased fibrosis and fat accumulation, and marked
muscle weakness that might be the consequence of reduced
regeneration following muscle damage (Fukada et al., 2010;
Coley et al., 2016). However, myocardial pathology and
hemodynamic defects in the control DBA/2J mice indicate that
the DBA/2J-mdx mouse is a poor model of DMD cardiomyopathy
(Hakim et al., 2017).
A series of variants with mutations in different parts of the murine
Dmd were developed (Danko et al., 1992), although some of these
retain a low level of full-length dystrophin expression (Danko et al.,
1992). Another mouse mutant, lacking many of the smaller
isoforms of dystrophin, has been generated by gene targeting: the
mdx52 mouse (Araki et al., 1997). Despite some differences from
the standard mdx mouse, there is still the problem of limited, if any,
clinical signs of muscular dystrophy.
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It has been shown that utrophin, an autosomal homologue of
dystrophin, precedes the expression of dystrophin during muscle
development (Clerk et al., 1993), and it has been suggested that
utrophin could substitute, at least in part, for dystrophin. The Davies
laboratory has shown that increased utrophin expression can prevent
the development of muscular dystrophy in the mdx mouse (Perkins
and Davies, 2002). Mdx mice have been crossed with utrophin
knockout (KO) mice to produce a double KO, which has a more
severe dystrophic phenotype than the mdx mouse (Deconinck et al.,
1997). Although this mouse is arguably a better phenocopy of DMD,
patients do not actually lack both dystrophin and utrophin. This
double-KO model is thus clearly unsuitable for screening all possible
therapies for DMD, as those that act via mechanisms that include the
upregulation of utrophin will fail to show a therapeutic effect.
Rat models of DMD have been generated recently using genome
modification techniques (Larcher et al., 2014; Nakamura et al.,
2014). Larcher and colleagues engineered theirs using TALENs
targeting exon 23. The muscles showed severe fibrosis and some
adipose tissue infiltration, unlike the mdx mouse with the same
mutation. The rats showed muscle weakness and decreased activity,
as well as evidence of cardiac remodelling and altered diastolic
function. Nakamura and colleagues used CRISPR-Cas9 to target
exons 3 and 16, producing a range of mutations in the Dmd gene in
the founder rats. The founder males showed clear evidence of
dystrophic pathology and carrier females with mutations in exon 16
successfully produced affected males. Dystrophic rats showed
greater fibrosis of the heart at an earlier age than the mdx mouse,
but with no clear evidence of functional cardiomyopathy. No
subsequent peer-reviewed papers have been published to date for
either rat model, although further studies on the Larcher rat have
been presented at several meetings.
Cats with dystrophin-deficient muscular dystrophy have been
described, but are not suitable as experimental models for human
DMD, as they suffer from hypertrophy of the diaphragm and tongue,
which makes eating and drinking very difficult for the affected
animals (Gaschen et al., 1999).
A number of different breeds of dogs presented at veterinary clinics
have been diagnosed with dystrophin-deficient muscular dystrophy.
Several of these have been subsequently used to develop dog models
of DMD, the most common being a Golden Retriever with Muscular
Dystrophy (GRMD), also known as CXMD, which carries a splice
site mutation that leads to the loss of exon 7 and thus a failure to
produce dystrophin (Sharp et al., 1992). This model has been
distributed to a number of colonies worldwide, including sites in the
USA, France and Brazil. While these dogs do show clear clinical
signs analogous with DMD, there are some significant differences. A
number of the GRMD dogs die within the first 6 months of life and
there is considerable dog-to-dog variation, which, with the small
numbers available for each experimental group, makes it difficult to
show clear statistically significant results. In contrast to GRMD dogs,
DMD neonates do not show enhanced early mortality.
Another dog model (deltaE50-MD dog), carrying a splice site
mutation leading to the loss of exon 50, is under development at
the Royal Veterinary College (London, UK) based on an index case
identified in 2009 (Walmsley et al., 2010). A carrier half-sister of
the index case has been bred onto the Beagle background and the
colony is currently undergoing a natural history study. Preliminary
data were presented in a series of posters at the 2018 UK
Neuromuscular Translational Research Conference (Riddell et al.,
2018). To date, the phenotype of the affected deltaE50-MD dogs
has proved fairly consistent, with clear clinical signs of the disease
and without an increased neonatal mortality.
The pig is an attractive option for translational studies, as it is a
very similar size to humans and could thus be a good test of potential
problems when scaling up a therapy first tested in mice before
translating it for use in humans. Klymiuk et al. (2013) used gene
targeting to delete exon 52 of the porcine DMD gene. However,
these pigs die prematurely, often in the first week of life, and
survival appears to depend on the level of utrophin expression.
None of the pigs survive to breeding age and, to date, the production
of a carrier female has not been described.
Both dogs and pigs have immune systems that are closer to
humans, eat a diet more similar to ours and are of comparable sizes,
particularly to the pre-teenage years in humans, compared with
rodent models. In addition, large animal models of DMD clearly
demonstrate clinical signs of disease that can be used to assess
response to treatment in tests that have translational value for humans.
However, the use of such models is not without problems. Dogs only
come into oestrus twice a year and gestation is on average 63 days.
Pigs can be bred all year round but the gestation period is even
longer, at 114 days. Thus, breeding animals for experiments takes
considerably longer than mice (gestation period of 21 days) or rats
(gestation period of 21 to 24 days). Not only does it take longer for
large animals to reproduce, but they also require considerable space
per animal and have additional requirements for social interaction
with humans, all of which substantially increases the maintenance
costs per animal. Importantly, public perceptions of value differ
between the species with a high affinity with dogs, and therefore an
increased reluctance to see them being used as experimental animals
compared with public attitudes towards rodents.
Intriguingly, Sui et al. (2018) have just published a description of
a rabbit model for DMD. They used a CRISPR-Cas9 to target exon
51 of the Dmd gene to ablate dystrophin expression in a New
Zealand rabbit. About 20% of the DMD KO rabbits died within the
first 2 weeks after birth, and approximately half (42.6%) died by
20 weeks of age. The muscles of the surviving DMD KO rabbits
show histological pathology typical of DMD, although the degree
of fibre loss and fatty replacement was not quantified in this study.
The left ventricular ejection fraction and fraction shortening of the
DMD KO rabbits were significantly decreased compared with the
control rabbits at 16 weeks of age, suggestive of a developing
cardiomyopathy. Finally, DMD KO rabbits exhibited significantly
reduced mobility and inability to climb a step. Mobility was
measured using a fitness tracker and similar analyses of daily
activity have been proposed for human clinical trials.
Rabbits breed throughout the year in captivity and gestation is only
31 days, thus large numbers of animals can be bred rapidly. Although
the dystrophic rabbit is an improvedmodel comparedwith the various
mouse models, as the rabbits have clear clinical signs of the disease
but are substantially easier to breed and are less expensive than
dog models, it is not entirely clear how different this DMD rabbit is
from the rat models. Importantly, the rabbit model shows clear
cardiomyopathy, whereas there was no change in the ejection fraction
or fraction shortening in the only dystrophic rat paper that reported
cardiac function (Larcher et al., 2014). Unlike the rat models, the
rabbit described by Sui and colleagues has a high mortality by
5 months and the reasons for this should be investigated further.
If this mortality is caused by cardiomyopathy, as suggested by the
authors, then the rabbit model could prove to be the model of choice
for testing therapeutic drugs for the dystrophic heart.
So where are we now with animal models of DMD? We now have
mouse, rat, rabbit, pig and dog models of DMD, each with their own
particular properties. Is one model better than all the others? The
answer is clearly no. Rodent models allow us to breed sufficient
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numbers to power statistically robust studies, but they have limited
clinical signs that cannot be directly extrapolated to DMD. General
activity appears lower in rodent and the newly developed DMD rabbit
model, but it is not clear whether this reduction is sufficiently robust
for accurate drug screening, as some candidate drugs might inhibit
activity by, for example, inducing nausea; or increase activity by, for
example, stimulating the brain. Conversely, dog models, in which we
can undertake clinically relevant endpoints, such as the 6-min walk
distance and timed function tests, are difficult to breed in sufficient
numbers and are exceedingly expensive, which limits the statistical
power in the experiments. In some models, such as the dystrophic
rabbit, pig and GRMD, there is significant early mortality, which
does not resemble the human condition. There appears to be an effect
of body size, whereby the severity of clinical signs increases with
increasing body size across the species. Indeed, within the dog breeds,
the phenotype of theGRMDmutation is less severewhen bred onto the
smaller Beagle background (Walmsley et al., 2010). Perhaps we need
to consider which stages of DMD we intend to model by the different
animals. A consideration based not on the relative age of each species,
but on their pathological presentation could be more relevant to their
translational impact. Hence, the mdx mouse is a model of the
neonate to 3-year-old DMD boy, whereas the GRMD dog model is
closer to a 5- to 10-year-old DMD boy. The new rabbit model
generated by Sui and colleagues might fill a gap between the
mouse and the dog, and could prove to be particularly useful for
testing drugs that can slow the cardiomyopathy, as this is currently
a major cause of death for patients with DMD. It is an exciting time
in DMD with a number of novel therapies entering the clinic and
even more in the pipeline. Owing to the rarity of DMD, it is
essential that we select only the most promising therapies for
clinical testing so as not to exhaust our limited number of the most
informative patients. A clear understanding of the limitations of
each animal model is vital for accurate interpretation of the results
of any pre-clinical therapeutic intervention and the potential for
translation into the clinic for the treatment of DMD.
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